Short Interest in Aptorum Group Limited (NASDAQ:APM) Decreases By 38.5%

Aptorum Group Limited (NASDAQ:APM) was the recipient of a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 62,491 shares, a drop of 38.5% from the June 15th total of 101,658 shares. Based on an average trading volume of 42,111 shares, the short-interest ratio is currently 1.5 days. Approximately 2.7% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Aptorum Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Aptorum Group currently has a consensus rating of “Sell”.

Aptorum Group Stock Performance

Shares of Aptorum Group stock traded up $0.01 on Friday, reaching $0.70. 167,078 shares of the stock were exchanged, compared to its average volume of 48,199. The firm’s 50 day moving average is $0.86 and its 200-day moving average is $0.89. Aptorum Group has a one year low of $0.60 and a one year high of $4.47.

Aptorum Group shares are set to reverse split before the market opens on Monday, July 20th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, July 19th.

About Aptorum Group

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.